News and Announcements
Actinogen Published in British Journal of Pharmacology
- Published February 09, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical is pleased to announce the research paper: Selection and early clinical evaluation of the brain-penetrant hydroxysteroid dehydrogenade type 1 inhibitor UE2343 (Xanamem™) has been published in the British Journal of Pharmacology.
KEY TAKEAWAYS:
- These Phase I results show Xanamem™ is safe and well tolerated with no major safety issues.
- Confirm the brain penetrating properties of Xanamem™ and that it reaches the brain at concentrations predicted to inhibit excess cortisol production in the brain.
- Xanamem™ is a good candidate to further investigate as a treatment for Alzheimer’s disease.
For more information please click below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
